BioPharmSignal logoBioPharmSignal

Biotech News

Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026

Syndax Pharmaceuticals (SNDX)Syndax PharmaceuticalsCommercial

NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will host an R&D Day on Tuesday, July 14, 2026, at 8:30 AM ET in New York City.

Related news

SNDXSyndax Pharmaceuticals2026-06-02 20:01 EST

Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data

SNDXSyndax Pharmaceuticals2026-08-04 20:01 EST

Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update

GERNGeron2026-07-22 20:01 EST

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GERNGeron2026-07-14 20:26 EST

Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

TEVATeva Pharmaceutical Industries2026-06-04 12:30 EST

Teva Expands European biosimilars portfolio with launch of AHZANTIVE® (aflibercept) biosimilar to Eylea®

RVMDRevolution Medicines2026-05-31 12:06 EST

Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer

REGNRegeneron Pharmaceuticals2026-06-25 20:05 EST

Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast

TEVATeva Pharmaceutical Industries2026-06-18 20:30 EST

Teva to Host Conference Call to Discuss Second Quarter 2026 Financial Results on July 29, 2026 at 8 a.m. ET

CGEMCullinan Therapeutics, Inc.2026-06-10 11:30 EST

Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases

REGNRegeneron Pharmaceuticals2026-06-04 11:00 EST

Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO

View all latest news

Syndax Pharmaceuticals

Commercial Oncology Portfolio Syndax Pharmaceuticals develops and commercializes therapies for genetically defined leukemias and immune-mediated complications of transplantation. Its commercial portfolio is built around Revuforj and Niktimvo. Revuforj Revuforj, or revumenib, is a menin inhibitor used in acute leukemias with susceptible...

Recent company news

SNDXSyndax Pharmaceuticals2026-08-04 20:01 EST

Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update

SNDXSyndax Pharmaceuticals2026-07-28 11:00 EST

Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026

SNDXSyndax Pharmaceuticals2026-07-14 12:00 EST

Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event

SNDXSyndax Pharmaceuticals2026-06-11 11:03 EST

Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026

SNDXSyndax Pharmaceuticals2026-06-11 11:00 EST

Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology

Stock data

Close
19.76 USD
Market cap
1.63B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States